氨磺必利与利培酮治疗精神分裂症的疗效及不良反应的比较研究

目的：比较和研究氨磺必利与利培酮治疗精神分裂症的临床疗效和不良反应。方法：将118例精神分裂症患者随机分为研究组和对照组，研究组（n=59）给予氨磺必利，起始剂量0．2evd，每日2次；对照组（n=59）给予利培酮，起始剂量1mevd，每日1次。1周内氨磺必利加至0．9～1．2eva，利培酮加至3～6mevd，然后根据病情需要及不良反应情况进行调整。治疗时间为8周，采用阳性与阴性症状量表（PANSS）和副反应量表（TESS）评定其疗效和不良反应。结果：研究组总有效率为88．14％，对照组总有效率为84．75％，两组有效率相比较，差异没有显著性（≯=0．289，P=0．600），PANSS量表中阳性症状评分，研究组（13．49±1．60）与对照组（13．65±1．78）相比较无明显差异（P〉0．05）；但阴性症状评分中研究组为（12．69±1．86），明显优于对照组（17．99±1．81）（P〈0．05），副反应量表TESS中研究组治疗后行为表现、化验、神经系统、自主神经系统、心血管系统及总评A与对照组相应指标相比较，差异有统计学意义（P〈0．05）。研究组的体重增加显著少于对照组（P〈0．05）。结论：氨磺必利治疗精神分裂症总体疗效明显优于利培酮，且体重增加显著减少。

The comparative analysis of Amisulpride and Risperidone on treating the Schizophrenia

Objective：To compare and study the clinical effects and untoward reactions of Amisulpride and Risperidone on treating schizophrenia. Methods： 118 patients with Schizophrenia were randomly divided into treatment group which was treated with Amisulpride, starting dose 0.2 g/d, 2 times a day; while the controlled group was treated with Risperidone starting dose 1 rag/d, once a day. In 1 week Amisulpride was added to 0.9 ~ 1.2 g/d, while Risperdal was added to 3 - 6 mg/d, then adjusted according to the illness and untoward reactions situation. All of them were treated and observed for eight weeks. The efficacy were assessed by Positive and Negative Symptoms Scales （PANSS） and untoward reactions were assessed by Treatment Emergent Symptoms Scale （TESS）. Re- suits： The total effective rate of treatment group was 88.14%, the total effectiveness of the control group was 84.75%, comparing effi- cient of two groups, there was no significant difference （x2 =0. 289, P =0.600） ,the positive symptom score of PANSS scale, that of the treatment group was （ 13.49 _＋ 1.60） and that of control group was （ 13.65 ＋ 1.78 ）, comparing them, there was no difference obvi- ously （P 〉0.05） ; But the negative symptoms score of the treatment group was （ 12.69 -＋ 1.86） ,which was much better than that of control group（ 17.99 -＋ 1.81 ） （P 〈0.05）, comparing side effects TESS scale after treatment ,scale behavior, laboratory, nervous sys- tem, plant nerve system, cardiovascular system and total score A of the treatment group to those of the control group, there were statis- tically significant difference （P 〈 0.05）. The weight increasing of the treatment group was significantly less than the control group （P 〈 0.05 ）. Conclusions： Amisulpride is superior to Risperidone on treating schizophrenia, and weight increasing was significantly less than that of the control group.